Pre-commercial biotech with no revenue and binary Phase 3 readout expected Q1 2027. The completed enrollment is a modest de-risking step but the stock will remain range-bound until OPERA-01 top-line data. The Bayer collaboration for OP-3136 is a positive pipeline signal but not near-term price catalyst. Monitor enrollment progress in OPERA-02 and any early signals from the OP-3136 Phase 1 expansion cohorts.
Drugs in focus
OLMA drug pipeline →palazestrant
● Neutral Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If the OPERA-01 Phase 3 trial succeeds, palazestrant could potentially be filed for FDA approval in 2027, with a potential launch in 2028 at the earliest, assuming no regulatory delays.
- Next catalyst
- None dated
What to watchThe next hard catalyst is the SABCS 2026 presentation in December 2026, where Olema will show combination data for palazestrant with ribociclib and for its KAT6 inhibitor OP-3136. The truly binary event is the OPERA-01 Phase 3 monotherapy topline readout, now guided for Q1 2027. A positive readout would validate palazestrant as a potential best-in-class oral SERD/CERAN and likely drive a significant re-rating given the stock's current ~$7 price vs. a ~$36.50 mean analyst target. A negative or mixed result would be severely punishing given the company's high cash burn and near-total dependence on this single asset.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $10.43entry
- T+1 · 3mo ago +0.10%α −0.15% · $10.44
- T+5 · 3mo ago +2.11%α +2.51% · $10.65
- T+20 · 2mo ago −0.67%α +0.39% · $10.36
- T+60 · 13d ago −27.71%α −27.22% · $7.54
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Olema Oncology's Q2 2026 net loss widened to $63.2M (vs $43.8M a year ago) on higher R&D and G&A spending, but cash of $461.1M is ample to fund operations. The key catalyst is the completion of enrollment in the Phase 3 OPERA-01 trial, with top-line data now expected in Q1 2027, a de-risking milestone that brings the company closer to potential commercial launch. The Bayer collaboration for OP-3136 in prostate cancer also adds pipeline optionality, though the stock remains pre-revenue and binary on clinical outcomes.
Key Facts
- Completed enrollment in pivotal Phase 3 OPERA-01 trial; top-line data expected Q1 2027
- Cash, cash equivalents, and marketable securities: $461.1 million as of June 30, 2026
- Q2 2026 net loss: $63.2 million, compared to $43.8 million in Q2 2025
- GAAP R&D expenses: $57.8 million (vs $43.9 million in Q2 2025)
- GAAP G&A expenses: $9.4 million (vs $4.0 million in Q2 2025)
- Announced clinical trial collaboration with Bayer to evaluate OP-3136 in combination with darolutamide in metastatic castration-resistant prostate cancer
- GAAP EPS for Q2 2026: $(0.61) per basic/diluted share
- Weighted average shares outstanding: 104.5 million (basic/diluted)
Financial Impact
Cash burn rate increased; net loss of $63.2M in Q2 2026 vs $43.8M in Q2 2025, but $461.1M cash runway extends into 2027 beyond the OPERA-01 data readout
Risk Factors
- Phase 3 OPERA-01 could fail to meet its primary endpoint, destroying value
- No approved products or revenue, 100% dependent on palazestrant and pipeline
- Cash burn at ~$63M/quarter; though $461M provides runway into 2027, any delays in data or development could necessitate dilutive financing
- Highly competitive breast cancer space (Pfizer, Novartis, Lilly, AstraZeneca all active); commercial launch execution risk if palazestrant succeeds
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342186 |
Track record
20 reports on OLMA
1 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +38.44% at T+60 after the Aug 9, 2026 report. 1 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.29 Now $7.36 +0.96% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $7.56 Now $7.36 −2.65% settles Feb 11
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $7.27 Now $7.36 +1.24% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $7.33 Now $7.36 +0.41% settles Feb 4
- Oct 16, 20264w ago SC 13D/A Neutral 2/10 Entry $7.11 Now $7.36 +3.52% settles Jan 14
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $6.58 Now $7.36 +11.85% settles Jan 13
- Oct 2, 20266w ago Press Release Neutral 2/10 Entry $8.25 Now $7.36 −10.79% settles Dec 30
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Viewing Entry $10.43 to $7.54 Now $7.36 −29.43% ▼ −27.71% −27.22% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bearish 6/10 Entry $11.94 to $7.35 Now $7.36 +38.36% ▲ +38.44% +36.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers